Netflix, NetraMark, Novo Nordisk – Positive signals

Netflix – Earnings above forecasts

"Sell on good news" might be the motto for the streaming provider after its second-quarter 2025 results. Netflix performed significantly better than analysts had expected in the second quarter of 2025. The streaming giant increased its earnings per share from USD 4.88 in the same quarter last year to USD 7.19, exceeding consensus estimates of USD 7.02.

Netflix also sent a strong signal in terms of revenue, climbing from USD 9.56 billion to USD 11.08 billion. This also put the Company slightly above analyst expectations of USD 11.06 billion.

The US company plans to increase its use of artificial intelligence in the future. AI is expected to not only reduce production costs, but also improve the quality of films and series.

The Argentine Netflix series El Eternauta provides a concrete example. In it, an elaborate scene involving the collapse of a building in Buenos Aires was realized entirely with the help of AI. According to Sarandos, the sequence was not only significantly cheaper to produce, but also around ten times faster than using traditional special effects. This is the first AI-generated scene to be released in the streaming giant's portfolio.

Despite the excellent figures, investors tended to take profits, with Netflix shares falling by over 5% to USD 1,209. Analysts at DZ Bank continue to see the stock as a "Buy" candidate following the release of the figures and have set a price target of USD 1,500.

NetraMark – Impressive development

The latest results published by the disruptor in the healthcare sector can be described as nothing short of outstanding. Canadian company NetraMark is aiming for a paradigm shift in clinical research with its NetraAI platform. The use of artificial intelligence is intended to significantly help reduce the alarmingly high failure rate of clinical trials, especially in the capital-intensive Phase 3. Approximately 90% of projects currently fail between the stages of drug development and approval. NetraMark's data-driven approach thus addresses one of the biggest challenges facing the pharmaceutical industry.

In a recent comparative study, NetraMark pitted its NetraAI platform against leading AI systems, including ChatGPT, DeepSeek, and classic machine learning methods. Three demanding clinical data sets served as the basis for the study. NetraAI was the only system to deliver clinically relevant and statistically robust insights, representing a breakthrough in the data-driven understanding of complex diseases.

The key lies in the platform's ability to work with a small number of highly relevant variables. This leads to more precise inclusion criteria, accelerates the recruitment of suitable subjects, and significantly improves study design.

Another key advantage of NetraAI is its clear distinction between highly predictable and uncertain patient groups. While other models inevitably provide a prognosis even when the data is uncertain, NetraAI focuses specifically on transparency and explainability. This minimizes placebo effects, reduces the risk of wrong decisions, and increases the likelihood of study success.

This combination of precision, robustness, and traceability makes NetraAI a potential game changer in medical research. NetraMark currently has a market capitalization of CAD 117.14 million. If the positive development continues, an upgrade is likely inevitable in the medium term.

Novo Nordisk – Exploring new paths

Things have gone quiet around Novo Nordisk, once a stock market darling and, for a time, the most valuable company in Europe. However, since July last year, the Danish company specializing in weight loss products has seen its share price fall by over 60% at its peak. Initial attempts at recovery were quickly halted, with the share price once again testing the support level of USD 60.

Now, the pharmaceutical giant is taking a new direction, investing EUR 80 million through its Novo Nordisk Foundation, in partnership with the Danish government, to help develop a quantum computer called "Magne." The system is being developed by Microsoft and US start-up Atom Computing, and will be operated by the newly established company QuNorth. Starting in 2027, the quantum computer will be made available to companies and researchers in fields such as chemistry, pharmaceuticals, logistics, and finance.

The investment is part of Denmark's digital strategy and aims to strengthen Europe's position in quantum technology. The aim is to attract talent and capital and expand the industrial technology base.

The streaming service Netflix beat analyst expectations on both revenue and profit. Novo Nordisk is investing in quantum computing. NetraMark's tests delivered impressive results compared to conventional language models.